Bivalirudin is a synthetic 20 amino acid peptide rationally designed based on structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin is sold under the brand name Angiomax and is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). It is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Bivalirudin directly inhibits thrombin by binding simultaneously to its active catalytic site and its substrate recognition site.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P00734|||Q9UCA1 Gene ID: 2147.0 Gene Symbol: F2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11833835 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ANGIOMAX Approved UseAngiomax™ is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Launch Date9.7683839E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Thrombin-specific inhibition by and slow cleavage of hirulog-1. | 1992 May 1 |
|
Development and current applications of thrombin-specific inhibitors. | 2001 Jun |
|
Bivalirudin: a new approach to anticoagulation. | 2001 Mar-Apr |
|
Current developments in antithrombotic therapy: the role of antithrombin agents. | 2002 |
|
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. | 2002 |
|
Bivalirudin: a review of its potential place in the management of acute coronary syndromes. | 2002 |
|
Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition. | 2002 Apr |
|
New drugs 2002. Part II. | 2002 Apr |
|
Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. | 2002 Apr |
|
Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures. | 2002 Aug |
|
Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty. | 2002 Aug |
|
Direct thrombin inhibitors in acute coronary syndromes. | 2002 Aug 10 |
|
Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. | 2002 Dec |
|
Current anticoagulation options in percutaneous intervention: designing patient-specific strategies. | 2002 Fall |
|
Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. | 2002 Feb |
|
Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. | 2002 Jun |
|
The role of thrombin inhibition during percutaneous coronary intervention. | 2002 Jun |
|
A practical cost analysis of bivalirudin. | 2002 Jun |
|
Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. | 2002 Jun |
|
Absolute and relative truth in clinical trials. | 2002 Jun 1 |
|
Reversing anticoagulants both old and new. | 2002 Jun-Jul |
|
Percutaneous coronary intervention with bivalirudin anticoagulation, immediate sheath removal, and early ambulation: a feasibility study with implications for day-stay procedures. | 2002 Mar |
|
[What is new in antithrombotic treatment?]. | 2002 Mar-Apr |
|
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). | 2002 May |
|
Gateways to clinical trials. | 2002 Oct |
|
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. | 2002 Sep |
|
Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood. | 2003 |
|
Direct thrombin inhibitors in cardiac disease. | 2003 |
|
Management of thrombotic and cardiovascular disorders in the new millenium. | 2003 Apr |
|
Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention? | 2003 Aug |
|
Clinician update: direct thrombin inhibitors in acute coronary syndromes. | 2003 Feb |
|
The evolving role of direct thrombin inhibitors in acute coronary syndromes. | 2003 Feb 19 |
|
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. | 2003 Feb 19 |
|
Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. | 2003 Jan-Feb |
|
Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits. | 2003 Jul |
|
Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia [corrected]. | 2003 Jul |
|
Bivalirudin in peripheral vascular interventions: a single center experience. | 2003 Jul |
|
Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study. | 2003 Jun |
|
Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure. | 2003 Mar |
|
Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study. | 2003 Mar 15 |
|
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. | 2003 Mar 15 |
|
Predicting the pharmacology of thrombin inhibitors. | 2003 May |
|
Direct thrombin inhibitors. | 2003 May |
|
Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. | 2003 May 1 |
|
A 24-hour continuous infusion study of bivalirudin in the rat. | 2003 May-Jun |
|
Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention. | 2003 Nov 1 |
|
Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. | 2003 Oct |
|
Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where? | 2003 Oct |
|
Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. | 2003 Oct 15 |
|
Bivalirudin in percutaneous coronary intervention. | 2003 Sep 15 |
Patents
Sample Use Guides
The recommended dosage of Angiomax (bivalirudin) is an intravenous (IV) bolus dose of 1.0 mg/kg followed by a 4-hour IV infusion at a rate of 2.5 mg/kg/h. After completion of the initial 4-hour infusion, an additional IV infusion of Angiomax may be initiated at a rate of 0.2 mg/kg/h for up to 20 hours if needed.
Route of Administration:
Intravenous
Substance Class |
Protein
Created
by
admin
on
Edited
Sun Dec 18 19:34:36 UTC 2022
by
admin
on
Sun Dec 18 19:34:36 UTC 2022
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
TN9BEX005G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
B01AE06
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
||
|
FDA ORPHAN DRUG |
200204
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
||
|
NDF-RT |
N0000175980
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
||
|
NDF-RT |
N0000175518
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TN9BEX005G
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
1076013
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
SUB05862MIG
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
385
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
M2581
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
DB00006
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
128270-60-0
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
FF-67
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
59173
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
C47415
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
TN9BEX005G
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
Bivalirudin
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
DTXSID00155847
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
7282
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
Bivalirudin
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY | |||
|
60819
Created by
admin on Sun Dec 18 19:34:37 UTC 2022 , Edited by admin on Sun Dec 18 19:34:37 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||